Used primarily in pharmaceutical research as an intermediate in the synthesis of bioactive compounds. Its structure supports the development of central nervous system agents, particularly those targeting neurological disorders. The compound's brominated dibenzazocine core enhances binding affinity to specific neural receptors, making it valuable in creating potential anticonvulsant or antipsychotic drug candidates. Additionally, the trifluoroacetamide group improves metabolic stability, which is beneficial for optimizing drug half-life and bioavailability during preclinical development.